| Autor: |
Kounatidis, Dimitris, Tentolouris, Nikolaos, Vallianou, Natalia G., Mourouzis, Iordanis, Karampela, Irene, Stratigou, Theodora, Rebelos, Eleni, Kouveletsou, Marina, Stamatopoulos, Vasileios, Tsaroucha, Eleni, Dalamaga, Maria |
| Předmět: |
|
| Zdroj: |
Metabolites (2218-1989); Jul2024, Vol. 14 Issue 7, p388, 49p |
| Abstrakt: |
Atherosclerotic cardiovascular disease poses a significant global health issue, with dyslipidemia standing out as a major risk factor. In recent decades, lipid-lowering therapies have evolved significantly, with statins emerging as the cornerstone treatment. These interventions play a crucial role in both primary and secondary prevention by effectively reducing cardiovascular risk through lipid profile enhancements. Beyond their primary lipid-lowering effects, extensive research indicates that these therapies exhibit pleiotropic actions, offering additional health benefits. These include anti-inflammatory properties, improvements in vascular health and glucose metabolism, and potential implications in cancer management. While statins and ezetimibe have been extensively studied, newer lipid-lowering agents also demonstrate similar pleiotropic effects, even in the absence of direct cardiovascular benefits. This narrative review explores the diverse pleiotropic properties of lipid-modifying therapies, emphasizing their non-lipid effects that contribute to reducing cardiovascular burden and exploring emerging benefits for non-cardiovascular conditions. Mechanistic insights into these actions are discussed alongside their potential therapeutic implications [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
